Archives
-
Metformin HCl as a Translational Immunometabolism Tool
2026-09-05
Metformin Hydrochloride is more than a glucose-metabolism reagent. Its linked effects on hepatic gluconeogenesis, AMPK–ACC signaling, lipid handling, and cellular redox create a strategic framework for connecting metabolic perturbation with immune-function assays. This article outlines how translational researchers can validate that bridge without overstating the evidence.
-
Panobinostat-Induced Calcineurin Degradation in Myeloma
2026-09-04
The reference study identifies calcineurin catalytic subunit PPP3CA as a therapeutically relevant target of panobinostat in multiple myeloma. Its experiments connect PPP3CA abundance with advanced disease and bortezomib resistance, while showing that calcineurin-directed combinations can improve antimyeloma activity and suppress osteoclast formation.
-
From Thermal Shifts to Translational Insight
2026-09-04
Translational research increasingly depends on connecting phenotypic activity with direct evidence of ligand engagement. This thought-leadership article shows how thermal shift assay logic, orthogonal validation, and the DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) can help researchers move from broad screening to defensible mechanism-of-action hypotheses.
-
Faropenem Sodium: Workflow for PK and AMR Studies
2026-09-04
Faropenem sodium supports integrated antimicrobial, anaerobe, resistance, and renal transport workflows rather than a single endpoint assay. Its PBP-directed activity and Npt1-associated secretion profile allow researchers to connect bacterial inhibition with disposition-oriented experiments.
-
Toremifene Citrate: ER Assay Workflows
2026-09-03
Build more interpretable estrogen receptor experiments with Toremifene Citrate, from receptor-binding benchmarks to breast cancer cell proliferation and translational rodent studies. This workflow emphasizes concentration design, vehicle control, exposure timing, and troubleshooting for reliable hormone receptor modulation.
-
SR 11302: Translating AP-1 Blockade to Oncology
2026-09-02
A translational perspective on SR 11302 as a selective AP-1 transcription factor inhibitor, connecting tumor-cell assays, AP-1-driven chemoprevention, and emerging immune-context studies while defining the evidence needed for rigorous oncology development.
-
Protease Inhibitor Cocktail for OXPHOS Workflows
2026-09-02
Protect fragile signaling and mitochondrial proteins from extraction-related degradation with an EDTA-free, broad-spectrum formulation. This workflow connects controlled lysate preparation to Western blotting, Co-IP, kinase assays, and mechanistic OXPHOS studies involving LRPPRC inhibition and Dasatinib.
-
Ruxolitinib: Mechanism-First Immune Assay Design
2026-09-01
Ruxolitinib (INCB018424) is more than a JAK1/2 inhibitor: it is a practical tool for connecting pathway control with high-dimensional immune phenotyping. This guide translates its biochemical profile and recent murine sarcoma findings into better assay design, controls, and interpretation.
-
Rucaparib: A Causal Framework for DDR Assays
2026-09-01
Rucaparib (AG-014699) is a potent PARP1 inhibitor for dissecting DNA repair stress, radiosensitization, and cell-fate decisions. This article presents a causal assay framework that separates target engagement, persistent DNA breaks, transcriptional effects, and apoptosis.
-
Relative Versus Fractional Viability in Cancer Studies
2026-08-31
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response phenotypes. This framework improves interpretation of in vitro cancer pharmacology by incorporating response magnitude, composition, and timing rather than treating a single viability endpoint as a complete measure of cytotoxicity.
-
Metformin and Tendon Heterotopic Ossification
2026-08-31
A recent mouse Achilles tendon study identifies the Nr4a1/Wnt/β-catenin axis as a mechanistic link between Metformin HCl exposure and reduced heterotopic ossification. The work combines an in vivo tendon model, tendon-derived stem cell assays, transcriptomics, and pathway perturbation to show that metformin limits osteogenic differentiation rather than simply altering systemic glucose control.
-
Balsalazide: Evidence for Colon-Targeted 5-ASA
2026-08-30
The 2009 review by Wiggins and Rajapakse evaluated balsalazide as a colon-activated 5-aminosalicylic acid prodrug for mild-to-moderate active ulcerative colitis. Its central contribution was to connect azo-bond design, bacterial activation, clinical remission data, and comparative tolerability, while highlighting faster remission induction than mesalamine in the available evidence.
-
PMSF for Protease-Controlled Immune Assays
2026-08-29
PMSF is more than a routine extraction additive: it is a pre-analytical control for proteolysis in temporal immune and extracellular-vesicle assays. This article explains how its selective chemistry can strengthen interpretation of shrimp hemocyte epigenetic studies while clarifying important limitations.
-
20-HETE–TRPV1 Signaling in Chronic Dermatitis
2026-08-28
The reference study identifies elevated 20-HETE as a lipid mediator that activates sensitized TRPV1 channels on MrgprA3+ sensory neurons, helping explain why normally painful stimuli can provoke itch in chronic dermatitis. By combining behavioral, electrophysiological, chemogenetic, metabolomic, and pharmacological approaches, the work links lesional-skin metabolism to pathological sensory switching and highlights 20-HETE synthesis as a potential intervention point.
-
Okadaic acid: PP1/PP2A Workflow Guide
2026-08-28
Okadaic acid (A4540) provides a controlled way to inhibit serine/threonine phosphatases PP2A and PP1 when phosphorylation-dependent signaling or apoptosis-related endpoints must be interrogated. It is suitable for biochemical and cell-based studies with matched vehicle controls, but it should not be treated as a broad phosphatase inhibitor or as evidence that a downstream phenotype is specific to one pathway.